Appeal No. 2001-2303
Application No. 09/029,581
In summary, the anticipation rejection is reversed because
Brunner does not disclose “every limitation of the claimed
invention, either explicitly or inherently.” Glaxo Inc. v.
Novopharm Ltd., 52 F.3d 1043, 1047, 34 USPQ2d 1565, 1567 (Fed.
Cir.), cert. denied, 516 U.S. 3378 (1995).
DECISION
The decision of the examiner rejecting claims 1 through
8 under 35 U.S.C. § 102(e) is reversed.
REVERSED
KENNETH W. HAIRSTON )
Administrative Patent Judge )
)
)
) BOARD OF PATENT
JOSEPH L. DIXON ) APPEALS AND
Administrative Patent Judge ) INTERFERENCES
)
)
)
MAHSHID D. SAADAT )
Administrative Patent Judge )
KWH:hh
4
Page: Previous 1 2 3 4 5 Next
Last modified: November 3, 2007